TL;DR
This meta-analysis investigated the prognostic value of CD133 and SOX2, known cancer stem cell markers, in advanced cancer patients. The findings suggest that CD133 positivity is associated with worse cancer-specific survival and overall survival, while SOX2 positivity correlates with poorer disease-free and recurrence-free survival. These markers could potentially guide therapeutic strategies for advanced cancer.
What Problem Does This Paper Address?
Cancer remains a leading cause of mortality worldwide, and while treatments have improved for early-stage disease, advanced and metastatic cancers still present significant challenges. Identifying reliable prognostic markers is crucial for predicting patient outcomes and tailoring treatment strategies. Cancer stem cells (CSCs) are implicated in tumor growth, metastasis, and resistance to conventional therapies. CD133 and SOX2 are two prominent markers associated with CSCs, but their collective prognostic significance in advanced cancer patients has not been definitively established. This study aims to address this gap by synthesizing existing research through a meta-analysis.
Methods
The researchers conducted a systematic meta-analysis following PRISMA guidelines. They searched multiple databases (PubMed, EMBASE, EBSCO, Web of Science, Cochrane Library) for studies published before April 2018 that investigated the prognostic value of CD133 or SOX2 expression in advanced, metastatic, or recurrent cancer patients. Inclusion criteria required studies to report hazard ratios (HRs) with 95% confidence intervals (CIs) from multivariable analyses for various survival outcomes (OS, DFS, PFS, CSS, RFS). Data extraction followed REMARK guidelines, and study quality was assessed.
For data analysis, a random-effects model was employed to account for heterogeneity. Subgroup analyses were performed to explore potential sources of heterogeneity based on tumor type, study source, survival rate, sample type, age, testing method, treatment regimens, and sample size. Publication bias was assessed using Egger's and Begg's tests. Crucially, Trial Sequential Analysis (TSA) was utilized to control for random errors and determine if sufficient evidence existed to draw firm conclusions, or if additional studies were needed.
Datasets
This paper is a meta-analysis, meaning it synthesizes data from existing published studies. It does not introduce a new dataset or benchmark. The "datasets" in this context are the 18 eligible studies identified, comprising 1358 cases for CD133 analysis and 433 cases for SOX2 analysis.
Key Insights and Ideas
- CD133 and SOX2 as potential prognostic indicators: The study provides evidence that these CSC markers are not just indicators of stemness but also carry prognostic weight in advanced cancers.
- Differential prognostic impact: CD133 appears more strongly linked to overall and cancer-specific survival, while SOX2's impact is more pronounced on disease-free and recurrence-free survival.
- Subgroup specificities: The prognostic value of CD133 is not uniform across all cancer types or patient demographics. Notably, it showed a stronger association with poorer OS in Chinese patients and in older individuals (>60 years).
- Need for caution and further research: Despite the findings, the TSA indicated that the current evidence base is insufficient for definitive conclusions, highlighting the need for more robust, prospective studies.
- Therapeutic implications: The findings suggest that CD133 and SOX2 could serve as targets for novel molecular therapies in advanced cancer.
Key Results
- CD133 Positivity:
- Associated with worse Cancer-Specific Survival (CSS) (HR = 3.70, 95% CI = 1.09-12.54, P = 0.036).
- Slightly correlated with unfavorable Overall Survival (OS) (HR = 1.57, 95% CI = 0.99-2.51, P = 0.057).
- No significant association with Disease-Free Survival (DFS).
- Subgroup analysis showed CD133 positivity was linked to poorer OS in patients treated with adjuvant therapy and in Chinese patients.
- SOX2 Positivity:
- Associated with worse DFS (HR = 3.08, 95% CI = 1.76-5.40, P < 0.001).
- Associated with worse Recurrence-Free Survival (RFS) (HR = 1.736, 95% CI = 1.055-2.901, P = 0.033).
- No significant association with Progression-Free Survival (PFS).
- Trial Sequential Analysis (TSA): For most outcomes analyzed (CSS, OS for CD133, and DFS for SOX2), the TSA indicated that the cumulative Z curve did not cross the sequential monitoring boundary, suggesting that more clinical studies are needed to confirm the findings.
Limitations and Future Work
The authors acknowledge several limitations:
- Limited sample size: The number of included studies and patients, particularly for SOX2, was relatively small, which TSA confirmed as insufficient for definitive conclusions.
- Geographic bias: Most studies were conducted in China, Japan, and Europe, with a lack of data from other regions like the USA.
- Retrospective design: The majority of included studies were retrospective, with only two prospective studies.
- Heterogeneity: While subgroup analyses were performed, considerable heterogeneity was observed, and its sources could not be fully explained.
Future work should focus on:
- High-quality prospective studies: Blinded detection of CD133 and SOX2 expression in larger, prospective cohorts is essential to obtain more reliable evidence.
- Diverse cancer types: Further investigation across a broader range of cancer types, including colorectal, lung, breast, and head-neck cancers, is needed.
- Therapeutic targeting: Exploring CD133 and SOX2 as targets for molecular therapy in advanced cancer patients is a promising avenue.
Summary updated